Acute Coronary Syndromes - Tailoring Treatment Based on Risk Stratification

Citation:US Cardiology 2005;2(1):1-5

Open access:

The copyright in this work belongs to Radcliffe Medical Media. Only articles clearly marked with the CC BY-NC logo are published with the Creative Commons by Attribution Licence. The CC BY-NC option was not available for Radcliffe journals before 1 January 2019. Articles marked ‘Open Access’ but not marked ‘CC BY-NC’ are made freely accessible at the time of publication but are subject to standard copyright law regarding reproduction and distribution. Permission is required for reuse of this content.

Approximately five million people present to the emergency department (ED) each year with chest pain, and billions of dollars are spent on assessment and treatment. Many therapies are time-dependent, so rapid identification of patients with acute coronary syndrome (ACS) - unstable angina (UA) and acute myocardial infarction (MI) - at high risk for adverse outcomes is essential. Missed or inappropriately treated ACS carries important medicolegal consequences. This raises the issue of whether doctors should treat as many people as quickly as they can. As few as 10% to 30% of patients who present with symptoms of ACS subsequently prove to have ACS. As the proportion of patients with actual disease decreases, the benefits of the treatment decrease, while the number of adverse outcomes remains constant or potentially increases (if some patients have aortic dissection, for example). This article reviews the risk assessment and resultant management of patients with UA and non-ST-elevation MI (UA/NSTEMI). A treatment algorithm that evaluates the differences in UA/NSTEMI patients and those with STEMI will also be reviewed.

Risk Stratification

Acute MI is described as a rise and fall of serum cardiac markers, preferably troponin, and either ischemic symptoms, ischemic electrocardiogram (ECG) changes, or previous percutaneous coronary intervention (PCI).1 Angina is defined as discomfort that is induced by exercise and relieved by rest or nitroglycerine administration, and is classified according to severity, with class 3 angina occurring after walking one or two blocks or climbing one flight of steps. Unstable angina is defined as class 3 angina that is either new onset exertional angina, or increasing within the past two months, or occurring at rest for more than 20 minutes.2 As mentioned, the prevalence of actual ACS is much lower than the number of ED patients suspected of having ACS. The Multicenter Chest Pain Study showed that, between 1984 and 1986, 26% of patients admitted for possible ACS had acute MI and 28% had unstable angina. With greater recognition of missed disease by both the public and the medical community, however, these rates have declined. The same study found that, between 1990 and 1994, only 11% of these patients had acute MI and 33% had unstable angina.

The American Heart Association (AHA)/American College of Cardiology (ACC) risk stratification guidelines are shown in Tables 1 and 2. Generally, they involve a determination of:

  • whether the signs and symptoms of ACS are due to coronary artery disease (CAD); and
  • the risk of adverse events.

History, examination, ECG, and cardiac markers are used to categorize the patient with definite ACS, possible ACS, chronic stable angina, or a non-cardiac process.2 However, this approach has many limitations, including the practicality of using the suggested 28 elements to determine whether ACS symptoms are due to CAD and the 24 parameters to determine the risk of adverse events in the presence of ACS. Application of this approach can also yield perplexing results. A 35-year-old male with burning epigastric pain radiating to the chest for 25 minutes that is improved but not resolved in the ED with an antacid and with normal ECG and cardiac markers would be classified according to the guidelines as having intermediate risk of ACS due to CAD and a high risk of adverse events due to prolonged duration of chest pain at rest. In addition, most of the AHA/ACC risk stratification criteria are based on chest pain, but up to half of all acute MIs present without chest pain.

The larger problem is that symptoms predicting risk in patients who actually have disease are different to those that predict risk among patients with suspected disease. For example, pain radiating to the neck, jaw, or left arm in a patient suspected of having cardiac ischemia does not predict risk of major adverse outcomes, but it does predict risk of acute MI. Similarly, T-wave inversions do not predict adverse outcomes in a patient with suspected ischemia but do predict adverse outcomes in patients with confirmed acute MI.

The use of decision rules in general have not been shown to improve admission or discharge decision-making. However, they may be helpful in improving decision-making in inexperienced physicians.

An Alternative Approach

A simpler approach may be to determine whether they have the disease or not. Definite ACS can be diagnosed when confirmatory signs are seen, such as ischemia on ECG or diagnostic cardiac markers. For example, even in a patient with an atypical story, the presence of planar ST depression would confirm ischemia.

Probable ACS, or disease that is strongly suspected but not yet identified, can be considered when a patient has:

  • a concerning story;
  • abnormal but non-diagnostic ECG, such as ST segments or T-waves that are changed from a previous ECG; or
  • minimal but non-diagnostic elevation of cardiac markers (e.g. TnI=0.2 when 1.5 is diagnostic, or a 65-year-old male with chest pressure at rest radiating to the left arm and relieved with nitroglycerin, recent onset of exertional symptoms, and a non-specific ECG).

Patients who probably do not have ACS would include those atypical symptoms, an ECG lacking signs of ischemia or left bundle-branch block, and negative cardiac markers. This would apply to a 65-year-old man with previous coronary artery bypass graft (CABG), current sharp chest pains lasting seconds and not relieved with nitroglycerin, and an unchanged ECG.

ED physicians should also be aware of patient characteristics that increase risk such as advanced age, male sex, prior MI, known vascular disease, and diabetes. Ischemic ST-segment depression or elevation, or T-wave abnormalities, along with changes from previous ECGs, are important. Consideration of symptoms that increase the risk of ACS is important in decision-making and these include pain that is substernal, pressure-like, radiates, is similar to that experienced with a previous MI, worsens with exertion, and is not relieved by rest or nitrates. Other MI presentations such as syncope, shortness of breath (SOB), dizziness, and upper abdominal pain must also be considered.

Cardiac markers can be used to rule out acute MI when they are sampled over 18 hours. However, they can be used in an accelerated protocol to rule out acute MI in the low-risk patient. They cannot be used to rule out unstable angina. Elevations of cardiac markers above normal define acute MI. However, any patient with detectable troponin should be considered at increased risk.3 The American College of Emergency Physicians (ACEPÔÇÖs) policy for obtaining cardiac marker levels is to evaluate CK-MB mass and subforms at six to 10 hours from pain onset and cTnT and cTnI at eight to 12 hours. A baseline and second level of the markers is recommended.

Treatment and Risks

Selecting the appropriate treatment can be challenging when relying on clinical trial data, especially because the medications conferring the most benefit in the ACS patient population also have the potential for the most harm, primarily due to increased bleeding. Therefore, it is most prudent to consider each medication in terms of the number needed to treat (NNT) to prevent one mortality or morbidity case, versus the number needed to harm (NNH) - or the number of patients who will receive the medication before an adverse event is expected.

Uses, benefits, and risks of treatments for ACS associated with significant benefit as well as greater risk of bleeding are described below.


Heparin (intravenous (IV) unfractionated or low molecular weight heparin (LMWH)) is recommended for patients with suspected MI and UA with an NNT of 30 to 40 and an NNH of 70 to 90. However, these trials were performed in patients with positive cardiac markers or ischemic ECGs. It is not clear that these results can be extrapolated to patients without these findings of definite disease. LMWH appears to have slightly fewer adverse outcomes than IV unfractionated heparin.4 Dosing for IV unfractionated heparin is 60-70U/kg (maximum 5,000U) and 12-15U/kg/hour infusion (maximum 1,000U/hour). For LMWH, dosing for enoxaparin is 1mg/kg subcutaneous (SQ) twice-daily (bid) and for dalteparin, 120IU/kg SQ bid.

Glycoprotein 2b3a Inhibitors

Glycoprotein 2b3a inhibitors include abciximab for PCI only, and eptifibatide and tirofiban for both ACS and PCI. They are clearly beneficial in patients undergoing PCI, whether electively or for ACS with an NNT of 20 to 30. They are also suggested in patients with continuing ischemia, elevated troponin, and other high-risk features such as age over 75 years and accelerating symptoms.This is in spite of the fact that a meta-analysis of almost 20,000 patients with ACS who did not receive PCI showed no benefit from treatment with these agents.5,6


Clopidogrel is indicated for all ASA allergic patients and should be given immediately at a 300mg p.o. loading dose to those at high risk of UA/NSTEMI in whom catheterization is not anticipated in the next two to five days. The NNT to decrease death, MI, and stroke is 50. Again, clopidogrel has not been shown to benefit patients without positive cardiac markers or ischemic ECG.4,7


Thrombolytics are indicated in patients with ST-elevation of 1mm in two or more contiguous leads or presumed new left bundle branch block (LBBB) with symptoms of less than 12 hours. Each hour of delay in administration increases death by 1.6 per 1,000 patients treated. Thrombolytics are contraindicated in patients with history of cerebrovascular accident (CVA), known bleeding diathesis, severe uncontrolled hypertension, intracranial or intraspinal surgery during the previous two months, or active internal bleeding, as well as in those with intracranial neoplasm, aneurysm, or arterio-venous malformation (AVM).

Treatments with Lower Risk of Major Bleeding

Aspirin has the greatest risk/benefit ratio of any treatment for ACS. It should be given to all patients with an NNT of 20 to 25 to prevent death, MI, and CVA. Aspirin offers a clear benefit with minimal adverse events and is equivalent to thrombolysis in 30-day mortality reduction.

Oxygen is associated with unclear benefit, except in hypoxia, but confers minimal risk, while morphine should be given to those having true ischemia, although there is no evidence of outcomes benefit.

Angiotensin-converting enzyme (ACE) inhibitors are also recommended for all patients with acute MI, especially those with ngestive heart failure (CHF) but systolic blood pressure (BP) greater than 100mmHg. The NNT is 200 and ACE inhibitor therapy should be initiated within the first 24 hours after the patient has been observed to be stable. Statins are definitely indicated for secondary prophylaxis in documented CAD or primary prophylaxis in patients at very high risk.

Other treatments requiring more consideration are listed below.


Nitrates may cause coronary artery vasodilation and reduce preload/afterload. However, if hypotension occurs, the adverse effects significantly outweigh the benefits. Nitrates are definitely indicated in those with CHF, persistent ischemia, hypertension, or a large anterior MI in the first 48 hours. No clear benefit has been established in other MI patients. Nitrates should be used with caution in RV infarcts and are contraindicated if hypotension, tachycardia, or bradycardia of less than 50 are present. Sublingual nitrates should be started at 0.4mg. IV nitrates should be started at 10-20ucg/min and titrated by 10 to 20ucg every three to five minutes. IV nitrates are often underdosed - a dose of roughly 80ucg/min is equivalent to 0.4mg sublingual, and two inches of topical paste is equivalent to 40 to 120ucg/min.


These agents have an NNT of 66 to prevent death, MI, or cardiac arrest in ACS patients. Contra-indications include conduction blocks, significant asthma, LV dysfunction with CHF, hypotension, and bradycardia. IV metoprolol should be given at 5mg Q five minutes for 15 minutes than at 25 or 50mg p.o. every six hours.


PCI is the ideal therapy for STEMI patients and appears beneficial in non-STEMI/unstable angina patients with positive troponins or ST depression. PCI is associated with fewer adverse outcomes than thrombolytics. PCI should be performed within 90 minutes of the patient entering the ED by a physician who performs at least 75 of these procedures a year, and in an institution performing at least 200, but preferably 400, annually. Transferring a patient to a more experienced facility resulting in a delay of up to two hours may still have lower rates of adverse outcomes than the use of thrombolytics.


  1. Alpert J S,Thygesen K, Antman E, Bassand J P,Myocardial infarction redefined - a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction, J. Am. Coll. Cardiol. (2000), 36: pp. 959-969.
    Crossref | PubMed
  2. Braunwald E, Antman E M, Beasley J W, et al.,ACC/AHA, 2002: Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina), Circulation (2002), 106: pp. 1,893-1,900.
    Crossref | PubMed
  3. Morrow D A, Cannon C P, Rifai N, et al., Ability of minor elevations of troponins I and T to predict benefit from an early invasive strategy in patients with unstable angina and non-ST elevation myocardial infarction: results from a randomized trial, JAMA (2001), 286: pp. 2,405-2,412.
    Crossref | PubMed
  4. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction, Lancet (2001), 358: pp. 605-613.
    Crossref | PubMed
  5. Schriger D L, Herbert M E,Platelet glycoprotein inhibitors in patients with medically managed acute coronary syndrome: does the enthusiasm exceed the science?, Ann. Emerg. Med. (2001), 38: pp. 249-255.
    Crossref | PubMed
  6. Boersma E, Harrington R A, Moliterno D J,White H, Simoons M L,Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes, Lancet (2002), 360: pp. 342-343.
    Crossref | PubMed
  7. Yusuf S, Zhao F, Mehta S R, Chrolavicius S,Tognoni G, Fox K K,Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation, N. Engl. J. Med. (2001), 345: pp. 494-502.
    Crossref | PubMed
  8. Brunwald E, Mark D B, Jones R H, et al., Unstable angina: diagnosis and management, Rockville, MD:Agency for Health Care Policy and Research and the National Heart, Lung, and Blood Institute, US Public Health Service, US Department of Health and Human Services; 1994; AHCPR Publication No. 94-0602.